Compare GSIT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSIT | CTMX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | GSIT | CTMX |
|---|---|---|
| Price | $7.47 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 2.2M | ★ 3.0M |
| Earning Date | 01-29-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $24,024,000.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.07 |
| Revenue Growth | ★ 22.00 | N/A |
| 52 Week Low | $1.62 | $0.40 |
| 52 Week High | $18.15 | $4.66 |
| Indicator | GSIT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 53.05 |
| Support Level | $7.39 | $4.09 |
| Resistance Level | $8.16 | $4.43 |
| Average True Range (ATR) | 0.77 | 0.27 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 52.98 | 37.41 |
GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.